![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Curis to Co-Develop Cancer Drug With Genentech in the U.S.
Curis to Co-Develop Cancer Drug With Genentech in the U.S.
Curis, a therapeutic drug development company, has elected to exercise a co-development option with its collaborative partner, Genentech, and will now share in U.S. development costs and future net profits, if any, derived from sales in the U.S. of a therapeutic product candidate for the topical treatment of basal cell carcinoma. Basal cell carcinoma, a skin cancer, is the most common form of all human cancers with approximately 800,000 to 1,000,000 new cases every year in the U.S.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct